Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Roll-Over Study of DCR-PHXC in Primary Hyperoxaluria
2018-003099-10Phase 3Active
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Dec 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH) and hyperoxaluria, sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoints: Treatment-emergent adverse events and Serious adverse events. Started Dec 2018; status: active.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)hyperoxaluria
Beyond the preview
Go deeper on 2018-003099-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003099-10.